Evidence map›Paper›PMID 42100890›Full record

ArticleOncoimmunology2026

Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.

Julie Lécuelle, Caroline Truntzer, Debora Basile, Luigi Laghi, Luana Greco, Alis Ilie, David Rageot, Titouan Huppé, Jean-François Emile, Fréderic Bibeau and 4 more

Abstract read
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Julie LécuelleUniversité Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, Dijon, France.
Caroline TruntzerUniversité Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, Dijon, France.ORCID 0000-0003-0895-4813
Debora BasileDepartment of Medical Oncology, San Giovanni di Dio Hospital, Crotone, Italy.
Luigi LaghiDepartment of medicine and Surgery, University of Parma, Parma, Italy.
Luana GrecoMolecular Gastroenterology Laboratory, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Alis IlieUniversité Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, Dijon, France.
David RageotUniversité Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, Dijon, France.
Titouan HuppéUniversité Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, Dijon, France.
Jean-François EmileParis-Saclay University, Versailles SQY University (UVSQ), EA4340-BECCOH, Assistance Publique-Hôpitaux de Paris (AP-HP), Ambroise Paré Hospital, Smart Imaging, Service de Pathologie, Boulogne, France.
Fréderic BibeauDepartment of Pathology, Besançon University Hospital, Université Marie et Louis Pasteur, Besançon, France.
Julien TaïebDepartment of Gastroenterology and Gastrointestinal Oncology, CARPEM comprehensive cancer center, Georges-Pompidou European Hospital, AP-HP, Paris, Université Paris-Cité, SIRIC CARPEM, Paris, France.
Valentin DerangèreUniversité Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, Dijon, France.
Come LepageUniversité Bourgogne Europe, CHU Dijon Bourgogne, Service d'Hépato-gastroentérologie et oncologie digestive, INSERM, Fédération Francophone de Cancérologie Digestive, CTM UMR 1231, EPICAD team, Dijon, France.
François GhiringhelliUniversité Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team, Dijon, France.ORCID 0000-0002-5465-8305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prognostic stratification in stage III colon cancer remains poor, despite treatment advances. Tumor-infiltrating lymphocytes, particularly CD3+ T cells, are potential prognostic markers, but manual assessment is labor-intensive and not robust. This study aimed to develop a deep learning model for automated analysis of CD3-stained histological slides to improve prognostic prediction. A total of 1737 patients from three international cohorts (PETACC08, PRODIGE-13, and HARMONY) were analyzed. The deep learning model (VGG19) identified tumor core (TC) and invasive margin (IM) regions on CD3-stained slides. Features from VGG19 and UNI models were used to cluster patients using hierarchical classification. Prognostic performance was evaluated using disease-free survival (DFS) across training, internal validation, and external validation sets. Deep learning classifiers identified distinct patient clusters with significantly different DFS based on TC and IM. For both IM and TC analysis, patients in the favorable group had a better DFS in all sets (IM:

Indexed as

CD3 ComplexColonic NeoplasmsDeep LearningLymphocytes, Tumor-InfiltratingAgedClassification AlgorithmsCohort StudiesDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisCD3 Complexbiomarkerscolonic neoplasmsdeep learningprognosisTumour infiltrating lymphocytes

Identifiers

PMID42100890
PMCPMC13166210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.